CD274 and neoplasm: In this method, activated T cells, such as Chimeric Antigen Receptor T-cell (CAR-T) therapy or cancer vaccines, can react to antigens, recognize tumor cells, and exhibit higher specificity for antigens than the anticancer effect of anti-PD-L1 antibodies [35,38].